JP2003516930A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516930A5
JP2003516930A5 JP2001516518A JP2001516518A JP2003516930A5 JP 2003516930 A5 JP2003516930 A5 JP 2003516930A5 JP 2001516518 A JP2001516518 A JP 2001516518A JP 2001516518 A JP2001516518 A JP 2001516518A JP 2003516930 A5 JP2003516930 A5 JP 2003516930A5
Authority
JP
Japan
Prior art keywords
cells
epha2
antibody
metastatic
cell density
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/022670 external-priority patent/WO2001012172A1/en
Publication of JP2003516930A publication Critical patent/JP2003516930A/ja
Publication of JP2003516930A5 publication Critical patent/JP2003516930A5/ja
Pending legal-status Critical Current

Links

JP2001516518A 1999-08-17 2000-08-17 転移性疾患の治療 Pending JP2003516930A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925899P 1999-08-17 1999-08-17
US60/149,258 1999-08-17
PCT/US2000/022670 WO2001012172A1 (en) 1999-08-17 2000-08-17 Treatment of metastatic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007211840A Division JP2007306938A (ja) 1999-08-17 2007-08-15 転移性疾患の治療

Publications (2)

Publication Number Publication Date
JP2003516930A JP2003516930A (ja) 2003-05-20
JP2003516930A5 true JP2003516930A5 (cg-RX-API-DMAC7.html) 2008-06-05

Family

ID=22529456

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001516518A Pending JP2003516930A (ja) 1999-08-17 2000-08-17 転移性疾患の治療
JP2007211840A Pending JP2007306938A (ja) 1999-08-17 2007-08-15 転移性疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007211840A Pending JP2007306938A (ja) 1999-08-17 2007-08-15 転移性疾患の治療

Country Status (10)

Country Link
EP (2) EP2289940A3 (cg-RX-API-DMAC7.html)
JP (2) JP2003516930A (cg-RX-API-DMAC7.html)
AT (1) ATE324877T1 (cg-RX-API-DMAC7.html)
AU (1) AU6784400A (cg-RX-API-DMAC7.html)
CA (1) CA2380888A1 (cg-RX-API-DMAC7.html)
DE (1) DE60027768T2 (cg-RX-API-DMAC7.html)
DK (1) DK1242060T3 (cg-RX-API-DMAC7.html)
ES (1) ES2261230T3 (cg-RX-API-DMAC7.html)
PT (1) PT1242060E (cg-RX-API-DMAC7.html)
WO (1) WO2001012172A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
DZ3332A1 (fr) 2000-03-31 2001-10-11 Purdue Research Foundation Methode de traitement a l'aide de conjugues ligand-immunogene
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
NZ537458A (en) * 2001-01-23 2007-02-23 Primagen Holding B Means and methods for treatment evaluation
EP1225233A3 (en) * 2001-01-23 2003-01-08 Amsterdam Support Diagnostics B.V. Means and methods for treatment evaluation
EP1298221A1 (en) * 2001-09-28 2003-04-02 PrimaGen Holding B.V. Means and methods for treatment evaluation
DE60234782D1 (de) * 2001-09-28 2010-01-28 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
AU2003215190A1 (en) * 2002-02-15 2003-09-09 Millennium Pharmaceuticals, Inc. Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
EP1519956B1 (en) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
EP1505999A4 (en) 2002-05-23 2009-07-08 Purdue Research Foundation LOW-MOLECULAR PROTEIN-TYROSINE PHOSPHATASE (LMW-PTP) AS DIAGNOSTIC AND THERAPEUTIC TARGET
AU2004210463B2 (en) * 2003-02-07 2009-07-16 Ludwig Institute For Cancer Research Limited Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
AU2003900541A0 (en) * 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
CA2525929A1 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
WO2005016381A2 (en) * 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
KR20060135671A (ko) * 2003-11-20 2006-12-29 메디뮨 인코포레이티드 EphA2 작동성 모노클로날 항체 및 이의 사용 방법
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
BRPI0607450A2 (pt) 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
ZA200900545B (en) * 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
US20090022760A1 (en) 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
US20090047255A1 (en) 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
WO2009028639A1 (ja) * 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗epha2抗体
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 EphA2 N末端フラグメント抗体
US20210268098A1 (en) 2018-08-03 2021-09-02 Uab Research Foundation Methods and compositions for alphavirus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003741A1 (en) 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
ES2242437T3 (es) * 1998-11-20 2005-11-01 Genentech, Inc. Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.

Similar Documents

Publication Publication Date Title
Moro et al. CEA, CYFRA21-1 and SCC in non-small cell lung cancer
Garvine A dynamical system for classifying buoyant coastal discharges
Kind et al. Seismic images of the biggest crash on Earth
JP2015521733A5 (cg-RX-API-DMAC7.html)
JP2023531990A5 (cg-RX-API-DMAC7.html)
WO2004032842A3 (en) Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
JP2006502416A5 (cg-RX-API-DMAC7.html)
Ishizaka et al. Induction of calcium flux across the rat mast cell membrane by bridging IgE receptors.
DE69503903D1 (de) Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung
MXPA02012424A (es) Ensayo de combinacion de antigenos/anticuerpos para el virus de hepatitis c.
WO2002059280A3 (en) Chronic lymphocytic leukemia cell line and its use for producing an antibody
WO2001012840A3 (en) Anti-epha2 antibodies as a cancer diagnostic
JP2005516374A5 (cg-RX-API-DMAC7.html)
JP2018198599A5 (cg-RX-API-DMAC7.html)
Yan et al. Measurement of denitrification in the Changjiang River
KR860003022A (ko) 인체-인체 하이브리드 셀라인의 제조방법
DE69430313D1 (de) Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen
DK1135170T3 (da) Radiokonjugation af internaliserende antistoffer
JPS5332114A (en) Quantitative determination of antigen and antibody
EP0323802A3 (en) Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
HU910767D0 (en) Immunological detecting of metolachlor
Buchner et al. Expression of plakoglobin in renal cell carcinoma
HANZAWA A new type of Lepidocyclina with a multilocular nucleoconch from the Taito Mountains, Taiwan (Formosa)
KR850008620A (ko) Atl 바이러스 항체의 측정방법 및 시약
WO2007011615A3 (en) Quantitative stabilized cell reference control products and methods